Mark Bookbinder

798 total citations
16 papers, 455 citations indexed

About

Mark Bookbinder is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark Bookbinder has authored 16 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark Bookbinder's work include Protein Degradation and Inhibitors (12 papers), Peptidase Inhibition and Analysis (9 papers) and Prostate Cancer Treatment and Research (5 papers). Mark Bookbinder is often cited by papers focused on Protein Degradation and Inhibitors (12 papers), Peptidase Inhibition and Analysis (9 papers) and Prostate Cancer Treatment and Research (5 papers). Mark Bookbinder collaborates with scholars based in United States, India and Germany. Mark Bookbinder's co-authors include I Taylor, Ryan R. Willard, John Houston, Jennifer Pizzano, Andrew P. Crew, Lawrence B. Snyder, Craig M. Crews, Taavi K. Neklesa, Nicholas Vitale and Jing Wang and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Mark Bookbinder

14 papers receiving 445 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Bookbinder United States 8 399 207 119 57 32 16 455
Marc Buchwald Germany 7 351 0.9× 139 0.7× 98 0.8× 10 0.2× 30 0.9× 7 400
Daphné Dupéré-Richer United States 9 347 0.9× 62 0.3× 77 0.6× 14 0.2× 22 0.7× 18 409
Dong Hoon Lee South Korea 12 398 1.0× 132 0.6× 25 0.2× 25 0.4× 15 0.5× 14 458
Jeannene Butler United States 6 291 0.7× 111 0.5× 72 0.6× 20 0.4× 11 0.3× 8 417
MI Dawson United States 8 356 0.9× 74 0.4× 122 1.0× 16 0.3× 116 3.6× 12 411
Camilla Stapnes Norway 10 406 1.0× 100 0.5× 203 1.7× 7 0.1× 26 0.8× 11 481
Amriti R. Lulla United States 11 277 0.7× 135 0.7× 19 0.2× 42 0.7× 14 0.4× 24 434
Tatiana Erazo Spain 11 287 0.7× 72 0.3× 22 0.2× 17 0.3× 15 0.5× 15 374
Cristina Girardi Italy 10 252 0.6× 70 0.3× 21 0.2× 40 0.7× 25 0.8× 14 408
Jon A. Oyer United States 9 350 0.9× 48 0.2× 26 0.2× 19 0.3× 37 1.2× 14 414

Countries citing papers authored by Mark Bookbinder

Since Specialization
Citations

This map shows the geographic impact of Mark Bookbinder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Bookbinder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Bookbinder more than expected).

Fields of papers citing papers by Mark Bookbinder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Bookbinder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Bookbinder. The network helps show where Mark Bookbinder may publish in the future.

Co-authorship network of co-authors of Mark Bookbinder

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Bookbinder. A scholar is included among the top collaborators of Mark Bookbinder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Bookbinder. Mark Bookbinder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
DeCarr, Lynn B., Samantha L. Eaton, Deborah Witt Sherman, et al.. (2025). ABCL-796: ARV-393, a PROTAC BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors (SMIs) Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma (DLBCL) Models. Clinical Lymphoma Myeloma & Leukemia. 25. S760–S760.
2.
DeCarr, Lynn B., Elizabeth Bortolon, Mark Bookbinder, et al.. (2025). Abstract 1655: ARV-393, a PROTAC B-cell lymphoma 6 (BCL6) degrader, combined with biologics or small molecule inhibitors (SMIs) induces tumor regressions in diffuse large B-cell lymphoma (DLBCL) models. Cancer Research. 85(8_Supplement_1). 1655–1655. 1 indexed citations
3.
Smith, Katie, Jennifer Pizzano, Mark Bookbinder, et al.. (2025). Abstract B107: Preclinical activity of ARV-806, a PROTAC KRAS G12D degrader. Molecular Cancer Therapeutics. 24(10_Supplement). B107–B107.
4.
Smith, Kathryn E., Peter T. Nower, Jennifer Pizzano, et al.. (2023). Abstract PR09: KRAS-targeted PROTAC degraders are broadly efficacious against KRAS-dependent tumor models. Molecular Cancer Research. 21(5_Supplement). PR09–PR09. 2 indexed citations
5.
Snyder, Lawrence B., John J. Flanagan, Yimin Qian, et al.. (2021). Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer. Cancer Research. 81(13_Supplement). 44–44. 74 indexed citations
6.
Neklesa, Taavi K., Lawrence B. Snyder, Ryan R. Willard, et al.. (2019). ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.. Journal of Clinical Oncology. 37(7_suppl). 259–259. 153 indexed citations
7.
Qian, Yimin, Monica Andreoli, Mark Bookbinder, et al.. (2019). Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer. Cancer Research. 79(4_Supplement). P5–4. 106 indexed citations
8.
Cacace, Angela, John J. Flanagan, Michael Berlin, et al.. (2019). O5‐04‐05: A NEW THERAPEUTIC STRATEGY FOR TAUOPATHIES: DISCOVERY OF HIGHLY POTENT BRAIN PENETRANT PROTACTM DEGRADER MOLECULES THAT TARGET PATHOLOGIC TAU PROTEIN SPECIES. Alzheimer s & Dementia. 15(7S_Part_31). 2 indexed citations
9.
Neklesa, Taavi K., Lawrence B. Snyder, Ryan R. Willard, et al.. (2018). An oral androgen receptor PROTAC degrader for prostate cancer.. Journal of Clinical Oncology. 36(6_suppl). 381–381. 14 indexed citations
10.
Qian, Yimin, Monica Andreoli, Mark Bookbinder, et al.. (2018). Abstract P4-04-04: Identification and development of oral estrogen receptor PROTAC degraders for breast cancer. Cancer Research. 78(4_Supplement). P4–4. 2 indexed citations
11.
Neklesa, Taavi K., Lawrence B. Snyder, Ryan R. Willard, et al.. (2018). Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer. Cancer Research. 78(13_Supplement). 5236–5236. 50 indexed citations
12.
Weed, Michael R., Laura J. Signor, Mark Bookbinder, et al.. (2017). Nicotinic alpha 7 receptor agonists EVP-6124 and BMS-933043, attenuate scopolamine-induced deficits in visuo-spatial paired associates learning. PLoS ONE. 12(12). e0187609–e0187609. 10 indexed citations
13.
Neklesa, Taavi K., Lawrence B. Snyder, Mark Bookbinder, et al.. (2017). An oral androgen receptor PROTAC degrader for prostate cancer.. Journal of Clinical Oncology. 35(6_suppl). 273–273. 23 indexed citations
14.
Neklesa, Taavi K., Lawrence B. Snyder, Mark Bookbinder, et al.. (2017). Abstract 5637: An oral Androgen Receptor PROTAC degrader for prostate cancer. Cancer Research. 77(13_Supplement). 5637–5637. 2 indexed citations
15.
Weed, Michael R., Mark Bookbinder, Rudolf N. Cardinal, et al.. (2015). Negative Allosteric Modulators Selective for The NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple Domains. Neuropsychopharmacology. 41(2). 568–577. 15 indexed citations
16.
Ramcharan, Eion J., et al.. (2004). Collicular Involvement in Macro-Square-Wave Eye Jerks in an Experimental Rhesus Monkey. Journal of Vision. 4(8). 766–766. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marc Buchwald Breakdown of academic impact, for papers by Daphné Dupéré-Richer Breakdown of academic impact, for papers by Dong Hoon Lee Breakdown of academic impact, for papers by Jeannene Butler Breakdown of academic impact, for papers by MI Dawson Breakdown of academic impact, for papers by Camilla Stapnes Breakdown of academic impact, for papers by Amriti R. Lulla Breakdown of academic impact, for papers by Tatiana Erazo Breakdown of academic impact, for papers by Cristina Girardi Breakdown of academic impact, for papers by Jon A. Oyer
Rankless by CCL
2026